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Abstract: Next-generation sequencing (NGS) technologies have revolutionized cancer
genomics due to their high throughput sequencing capacity. Reports of the gene mutation
profiles of various cancers by many researchers, including international cancer genome
research consortia, have increased over recent years. In addition to detecting somatic
mutations in tumor cells, NGS technologies enable us to approach the subject of carcinogenic
mechanisms from new perspectives. Deep sequencing, a method of optimizing the high
throughput capacity of NGS technologies, allows for the detection of genetic aberrations
in small subsets of premalignant and/or tumor cells in noncancerous chronically inflamed
tissues. Genome-wide NGS data also make it possible to clarify the mutational signatures of
each cancer tissue by identifying the precise pattern of nucleotide alterations in the cancer
genome, providing new information regarding the mechanisms of tumorigenesis. In this
review, we highlight these new methods taking advantage of NGS technologies, and discuss
our current understanding of carcinogenic mechanisms elucidated from such approaches.
Keywords: mutational signature; deep sequencing; next-generation sequencing;
inflammation-associated carcinogenesis; activation-induced cytidine deaminase; AID;
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1. Introduction
Recent innovations in next-generation sequencing (NGS) technologies have revolutionized cancer
genome research due to their high throughput sequencing capacity. In fact, whole-exome sequencing
(WES) and whole-genome sequencing (WGS) of various cancers using NGS technologies have led to
the identification of many genetic alterations in cancerous tissues. Most of these genetic alterations
might be passenger mutations that do not contribute to carcinogenesis, but some recurrently observed
mutations are likely to be oncogenic driver mutations. Recent WES and/or WGS studies have uncovered
some putative driver mutations by focusing on recurrently mutated genes among each cancer type. For
example, WES analysis of glioblastoma multiformes led to the discovery of a previously unknown
cancer-related gene, isocitrate dehydrogenase 1 (IDH1) that is recurrently mutated in glioblastoma
multiformes [1]. WES and/or WGS studies have also revealed particular profiles of genes mutated in
each cancer [2]. In gastric cancers, frequent mutations of several cancer-related genes, such as TP53,
ARID1A, and CTNNB1, were determined using WES and/or WGS [3–7]. Hepatocellular carcinomas
also have mutations of genes in several pathways, including the p53/RB pathway (TP53 and CDKN2A),
WNT pathway (CTNNB1 and AXIN1), and chromatin remodeling complex (ARID1A and ARID2) [8–10].
Thus, NGS technologies allowing for the accumulation of genome-wide sequencing data have elucidated
driver mutation profiles of various cancers in the field of cancer genomics.
NGS technologies have also enabled us to approach the subject of carcinogenic mechanisms from new
perspectives. Noncancerous tissues in premalignant conditions accumulate genetic aberrations before
apparent tumor development, but such genetic aberrations often exist only in low allele frequencies
and are thus difficult to detect by the classical Sanger sequencing method [11,12]. NGS technologies
applied to read selected target regions can generate high depth data and reveal gene alterations with
low allele frequencies. Identifying somatic mutations contained in noncancerous tissues by such (ultra-)
deep sequencing could provide clues to elucidating carcinogenic mechanisms because those mutations
might contribute to carcinogenesis at an early stage of tumor development. Moreover, analyses of the
entire picture of mutations accumulated in cancerous tissues revealed that each cancer has particular
mutational signatures reflecting its mutagenic mechanisms [13–15]. Thus, analysis of mutation profiles
obtained by NGS and identification of the characteristics of mutational signatures of the cancers will
lead to a better understanding of the underlying mutagenic processes. This review focuses on NGS
approaches to explore carcinogenic mechanisms and the current knowledge revealed by recent studies.
2. Deep Sequencing of Premalignant Inflamed Tissues Using NGS Technologies
2.1. Importance of Studying Genetic Alterations in Inflamed Noncancerous Tissues
Many clinical, epidemiological, and biological studies have demonstrated that various factors trigger
cancer development. Well-established mutagens, smoking and ultraviolet light, cause lung cancers
and skin cancers by inducing genetic aberrations, respectively [16–18]. Germline mutations of some
tumor suppressor genes strongly predispose to tumor development, as seen in familial polyposis coli
and Li-Fraumeni syndrome [19]. Chronic inflammation also predisposes to inflammation-associated
cancer development [20–22]. Especially in the gastrointestinal system, inflammation-associated cancers
develop in various organs; chronic gastritis due to Helicobacter pylori (H. pylori) infection causes gastric
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cancers; chronic hepatic inflammation with hepatitis C virus (HCV) causes hepatocellular carcinoma;
ulcerative colitis causes colitic cancers; and chronic duodenogastro-esophageal reflux and the resultant
inflammation cause Barrett’s esophagus and esophageal adenocarcinoma [21]. Epithelial cells exposed
to long-term inflammation have a strong potential for cancer development.
Cancer is a genome disease, and the accumulation of genetic aberrations in tumor-related genes is a
critical step in malignant transformation [23]. Genetic aberrations that occur during cancer development
accumulate in a stepwise manner, and mutations evoked by inflammation can be observed in inflamed
noncancerous tissues even before tumor development (Figure 1) [11,21,22,24–27]. Thus, it is reasonable
to assume that chronically inflamed epithelial cells play a role as the origin of inflammation-associated
cancers through the accumulation of genetic alterations.
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Figure 1. Scheme of accumulation of genetic alterations during inflammation-associated 
cancer development. Noncancerous tissues underlying chronic inflammation contain  
low-abundance mutated cells whose mutations can be detected as genetic alterations with 
low allele frequencies by (ultra-) deep sequencing. In contrast, cancerous tissues bear 
numbers of genetic aberrations including driver mutations (thorn-shaped), which are 
identified as mutations with relatively higher allele frequencies than those observed in 
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between cancerous tissues and their underlying noncancerous tissues. 
Figure 1. Scheme of accumulation of genetic alterations during inflammation-associated
cancer development. Noncancerous tissues underlying chronic inflammation contain
low-abundance mutated cells whose mutations can be detected as genetic alterations with low
allele frequencies by (ultra-) deep sequencing. In contrast, cancerous tissues bear numbers
of genetic aberrations including driver mutations (thorn-shaped), which are identified as
mutations with relatively higher allele frequencies than those observed in noncancerous
tissues. Some driver mutations in cancer-related genes may be shared between cancerous
tissues and their underlying noncancerous tissues.
Recent NGS studies identified numerous genetic alterations in cancerous tissues, most of which are
considered passenger mutations and only two to six of which are driver mutations that play a key role in
cancer development [28]. It is possible that mutations latently accumulated in premalignant tissues also
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include putative driver mutations, which could contribute to the early stage of carcinogenesis. Therefore,
studying genetic aberrations in noncancerous tissues could be a useful method for elucidating multistep
carcinogenesis processes during inflammation-associated cancer development.
2.2. Genetic Alterations in Inflamed Noncancerous Tissues Determined by Conventional
Sanger Sequencing
Several studies using the conventional Sanger sequencing method elucidated that noncancerous
tissues at risk for inflammation-associated carcinogenesis contain somatic mutations in cancer-related
genes. For example, Barrett’s esophagus epithelium represents premalignant lesions of esophageal
adenocarcinoma with somatic mutations in TP53 and CDKN2A genes, both of which are key tumor
suppressor genes involved in the development of esophageal adenocarcinoma [11]. Chronic hepatitis
tissues with HCV infection, which predisposes to hepatocellular carcinoma, bear TP53 mutations
at frequencies of 4–15 nucleotides per 104 nucleotides [26]. A sequencing study of colon crypts
isolated by laser capture microdissection revealed TP53 mutations in both premalignant dysplasia and
nondysplastic inflamed colon crypts of patients with ulcerative colitis [12]. These findings suggest
that chronically inflamed epithelia sustain founder mutations for carcinogenesis before malignant
transformation. Because of the low frequencies of cells with mutated genes in noncancerous tissues
(Figure 1), however, identifying pro-oncogenic mutations in noncancerous tissues by the Sanger method
requires much time and effort, and is still insufficient.
2.3. Deep Sequencing Analysis of Inflamed Noncancerous Tissues
Deep or ultradeep sequencing using NGS technologies, which often read each nucleotide more than
thousands of times, is an efficient tool for the detection of genetic alterations with very low frequencies
of mutated alleles [29]. For example, mutated alleles with frequencies as low as 1% or possibly even
0.1% can be detected by deep sequencing under conditions in which the error rate during the sequencing
process is properly evaluated and suppressed [7,29]. Taking advantage of the high sensitivity of NGS for
the detection of low-abundance mutations, recent studies identified somatic mutations of cancer-related
genes in noncancerous tissues with chronic inflammation in various organs.
TP53 mutations are most frequently detected in gastric cancer genomes, followed by ARID1A,
CTNNB1, and PIK3CA [3,4,30]. We performed deep sequencing on selected tumor-related genes in
H. pylori-related severe gastritis mucosa, which is considered to be a high-risk condition for gastric
cancer [7]. In the gastritis mucosa of 28 patients with gastric cancer, non-synonymous low-abundance
mutations in TP53 and ARID1A were detected in 11 cases (39.3%) and four cases (14.3%), respectively.
Interestingly, non-synonymous low-abundance mutations in TP53 and ARID1A were also detected in the
gastritis mucosa of patients without gastric cancer [7]. These findings suggest that various mutations
in tumor-related genes latently accumulate in H. pylori-related gastritis mucosa before histological
malignant changes.
Consistent with our findings, other recent studies revealed that the majority of recurrent mutations in
cancer-related genes detected in esophageal adenocarcinoma were found in Barrett’s esophagus [31–33].
Weaver et al. performed targeted deep sequencing analyses on esophageal adenocarcinoma tissues
and on benign metaplastic never-dysplastic Barrett’s esophagus and high-grade dysplasia, which are
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two key transition points in the development from premalignant Barrett’s esophagus to esophageal
adenocarcinoma [33]. Somatic mutations in 26 analyzed cancer-related genes were detected in 53% of
individuals with never-dysplastic Barrett’s esophagus and in 91% of those with high-grade dysplasia.
Furthermore, the vast majority of detected mutations had similar mutation frequencies among the
three disease stages, while TP53 was mutated exclusively in high-grade dysplasia and esophageal
adenocarcinoma, but not in never-dysplastic Barrett’s esophagus. Combined with accessional analyses,
the TP53 mutation status was found to differentiate never-dysplastic Barrett’s esophagus from high-grade
dysplasia and esophageal adenocarcinoma [33].
With regard to hepatobiliary tumors, we demonstrated that many genetic alterations accumulate in
the cirrhotic liver following HCV-related chronic hepatitis, a predisposing condition to hepatocellular
carcinoma [34]. Whole exome sequencing on nontumorous cirrhotic liver tissues led to the identification
of nucleotide alterations in a large quantity, comparable to those of hepatocellular carcinoma, while the
mutation frequencies in cirrhotic tissues tended to be lower than those in the matched tumor tissues.
Although the majority of the mutated genes detected in cirrhotic tissues were thought to be passenger
mutations, the leptin receptor gene (LEPR) was identified as a putative cancer-related gene mutated
in both cirrhotic tissues and hepatocellular carcinoma. Additional deep sequencing analyses on TP53,
CTNNB1, and LEPR genes revealed low-abundance mutations in more than half of the nontumorous
cirrhotic tissues analyzed. In addition, Jiang et al. reported whole exome sequencing on one dysplastic
nodule and two hepatocellular carcinomas in the same patient with HBV infection [35], and, consistent
with our results, several mutations were detected in dysplastic nodules as well as tumor tissues, although
there was no overlap in the mutations between dysplastic nodules and hepatocellular carcinomas. These
findings indicate that oncogenic mutations of genes related to hepatocarcinogenesis latently accumulate
in cirrhotic livers with viral infection.
Thus, deep sequencing analyses on inflamed noncancerous tissues have elucidated the accumulation
of putative pro-oncogenic mutations of cancer-related genes in the noncancerous tissues of various
organs during the process of inflammation-associated carcinogenesis.
3. Mutation Signatures Provide Clues to Predict Tumorigenic Mechanisms
3.1. Mutational Signatures Specific to Various Types of Cancers
Based on genome-wide mutation profiles of various cancers revealed by NGS technologies, each
cancer has a unique mutational signature [13–15]. Mutational signatures are classified according to the
type of mutations, such as substitution and small insertions and deletions (indels), and the sequence
contexts of the mutations [13]. With regard to single nucleotide substitutions, all substitutions can be
classified into 96 patterns by six patterns of base substitution (C:G>T:A, C:G>A:T, C:G>G:C, T:A>C:G,
T:A>A:T, T:A>G:C) and the bases immediately 5′ and 3′ to each substitution. This 96-substitution
classification is intelligible and well analyzed in many studies [13,36,37].
Several studies clarified that C:G>T:A transitions at XpCpG trinucleotides (X: any nucleotide,
under bar: mutated nucleotide) are the most prominent mutational signature in many types of cancers,
particularly gastrointestinal cancers (Figure 2) [13,14,36]. In addition, each type of cancer has its
own specific dominant mutational signature. In gastric cancer, C:G>T:A transitions at XpCpG sites
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as well as GpCpX sites are dominantly observed [6,7], and high rates of T:A>G:C transversions at
XpTpT sites (specifically at CpTpT sites) were also recently observed in some microsatellite-stable
gastric cancers [30,38]. C:G>T:A transitions at GpCpX sites and T:A>G:C transversions at XpTpT
sites are unique patterns of gastric cancer genomes. Esophageal cancers have two different histological
types: adenocarcinoma caused by duodenogastro-esophageal reflux, and squamous cell carcinoma,
whose risk factors are tobacco and alcohol. While T:A>G:C transversions at XpTpT sites are most
frequently observed in esophageal adenocarcinomas similar to some gastric cancers [33,39], C:G>T:A
transitions at XpCpG trinucleotides are the most predominant patterns in esophageal squamous cell
carcinoma, followed by C:G>G:C transversions and C:G>T:A transitions at TpCpX motifs [40–42].
Hepatocellular carcinoma has unique mutational signatures, such as T:A>C:G transitions in ApTpX
sequences and T:A>A:T transversions in CpTpG sequences, in addition to C:G>T:A transitions in
XpCpG motifs [9,43,44]. Interestingly, cholangiocarcinoma, another histological type of liver tumor,
does not have these characteristic mutational signatures [45,46]. In colorectal cancer and pancreatic
cancer, no specific mutational patterns have been detected, although some tumors with defective DNA
repair genes, including DNA mismatch repair genes, DNA polymerase genes, or BRCA1/2, exhibit
characteristic patterns [13]. These findings indicate that tumor mutational signatures differ based on
their origin.
3.2. Extrinsic and Intrinsic Mutagens and Mutational Signatures
Mutational signatures that accumulate in the cancer genome provide clues to identifying the cause
of genetic alterations during tumor development because many mutagenic agents and repair processes
have biased mutational patterns and preferred target nucleotide sequences [13,37,47,48]. For example,
loss of function in DNA repair genes induces specific patterns of genomic alterations. Tumors with
microsatellite instability in many cancer types have numerous substitutions and indels due to defects
of mismatch repair function caused by promoter methylation of MLH1 or mutations of MSH2, MSH3,
and MSH6 [49–51]. Tumors with mutations in POLE or POLD1 have extreme numbers of mutations
due to an impaired proofreading function of DNA polymerases [52,53]. Some tumors with inactivating
mutations of BRCA1 or BRCA2, such as some breast and pancreatic cancers, have substantial numbers
of larger deletions (up to 50 bp) with overlapping microhomology at breakpoint junctions [13,54].
By contrast, many toxigenic factors have been investigated as extrinsic mutagens. Ultraviolet light, a
well-known extrinsic mutagen, mainly induces C:G>T:A transitions in dipyrimidines, and accordingly
this mutation pattern is predominant in melanoma and basal cell carcinoma, providing evidence that
ultraviolet light is a causative factor in the development of these tumors [55,56]. Benzo[a]pyrene, a
convincingly established carcinogen contained in tobacco, is likely to cause C:G>A:T transversions,
and this mutation pattern is dominantly observed in lung cancers, especially in those associated with
smokers [13,57].
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Figure 2. Dominant mutational signatures in gastrointestinal cancers and their putative
contributors. (a) C:G>T:A transitio s at XpCpG trinucleotides are the most prominent
mutational signature in many types of cancers, including gastric cancer, esophag al
sq am us cell carcinoma, esophageal adenocarcinoma, and hepatocellular carcinoma, and
are considered to be related to spontaneous deamination of 5-methylcytosine; (b) C:G>T:A
transitions at GpCpX sequences, which are dominantly observed in gastric cancers,
accord with representative footprints of AID-mediated cytidine deamination; (c) T:A>G:C
transversions at XpTpT sites are uniquely observed in esophageal adenocarcinomas and
some microsatellite-stable gastric cancers, suggesting that some mutagenic processes
related to duodenogastro-esophageal reflux are shared between these cancers; (d) C:G>T:A
transitions at TpCpX sequences suggest the involvement of APOBEC3B in the development
of esophageal squamous cell carcinoma; (e) T:A>C:G transitions in ApTpX sites and
T:A>A:T transversions in CpTpG sites are characteristically detected in hepatocellular
carcinoma, whose causes remain to be determined.
As for intrinsic mutagens, several studies have demonstrated that apolipoprotein B mRNA editing
enzyme catalytic polypeptide (APOBEC) family members play an important role in the development of
various cancers by inducing genetic aberrations via their nucleotide-editing activity [36,58]. Among
APOBEC family members, activation-induced cytidine deaminase (AID) was first characterized by
its ability to induce genetic changes in genome DNA sequences and is considered to act as an
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intrinsic mutagen during the process of inflammation-associated carcinogenesis [21,59]. Under
physiological conditions, AID is expressed almost exclusively in activated B lymphocytes, and
contributes to generating antibody gene diversification by inducing somatic hypermutations and
class-switch recombinations of immunoglobulin genes [60,61]. On the other hand, inflammatory
stimulation elicits aberrant AID expression in epithelial cells and overexpressed AID could induce
mutations in various non-immunoglobulin genes and trigger inflammation-associated tumorigenesis,
including gastric carcinogenesis associated with H. pylori-related gastritis and hepatocarcinogenesis
associated with chronic hepatitis C [26,62,63]. AID deaminates C to U, resulting in the generation
of a U:G mismatch. This U:G mismatch is resolved by several pathways, such as the mismatch repair
system. If the mismatch is not repaired before the onset of DNA replication, DNA polymerase will insert
an A nucleotide opposite the U nucleotide, resulting in C:G>T:A transitions [64]. Such AID-induced
mutagenesis is genome-widely confirmed by experimental models in which AID predominantly caused
C:G>T:A transitions in the known preferred AID target sequence, i.e., WRCY motifs (W = A or T, R =
A or G, and Y = C or T) or RpCpX trinucleotides [47,65]. APOBEC3B, which is another member
of APOBEC family, is an enzyme that can induce genomic alterations in human genomes [36,66].
In contrast to AID, APOBEC3B exhibits a strong preference for deaminating C residues flanked by
T. Although the function of APOBEC3B in normal conditions is unknown, APOBEC3B expression
is correlated with frequencies of C:G>T:A transitions or C:G>G:C transversions in TpCpX motifs
in several types of cancer, including breast cancer and lung cancer [36,48]. In addition, foci of
localized hypermutations with an APOBEC3B-mediated pattern, referred to as kataegis, are often seen
in these cancers and are associated with genomic rearrangements [13,36,54]. These findings suggest
that APOBEC3B is related to the generation of both mutations and chromosomal aberrations in these
cancers. The mechanisms of APOBEC3B upregulation in these tissues, however, remain unknown.
3.3. Exploring Carcinogenic Mechanisms by Analyzing Mutational Signatures
Analysis of mutational signatures in cancers can be an effective method to explore carcinogenic
mechanisms as dominant mutational signatures observed in each cancer possibly reflect the mutagenic
mechanisms during carcinogenesis (Figure 2).
As for inflammation-associated cancers in gastrointestinal organs, AID is a promising key mutagen
that contributes to tumorigenesis via its DNA-editing activity. We previously demonstrated that AID is
aberrantly expressed in inflamed epithelial cells in various human organs [21,58], and AID transgenic
mice with constitutive and ubiquitous AID expression develop gastric cancers and hepatocellular
carcinomas via the mutagenic activity of AID [67]. Moreover, analyses of mutational signatures
strongly support the hypothesis that AID is involved in the development of H. pylori-related gastric
cancers. In gastric cancers, the most common mutation is C:G>T:A transitions, more than half of
which occur in XpCpG trinucleotides [3,4]. Such transition at the XpCpG site is the prominent
mutational signature in many types of cancer, and is considered to be related to spontaneous deamination
of 5-methylcytosine [13,68]. In addition, gastric cancers also have a preponderance of C:G>T:A
transitions at non-CpG sites, especially at GpCpX sequences [6,7]. Interestingly, this mutational pattern
corresponds well with the mutational signature induced by AID activity, suggesting the involvement of
AID-mediated cytidine deamination in the induction of somatic mutations during gastric carcinogenesis.
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Moreover, deep sequencing on selected cancer-related genes in nontumorous gastritis mucosa revealed
a strong preference for C:G>T:A transitions at GpCpX sequences, similar to those in gastric cancer
tissues [7]. These findings suggest that AID consistently contributes to the development of gastric cancer
from the initiation stage to the promotion stage.
In esophageal adenocarcinomas, the predominant mutational signature is T:A>G:C transversions with
striking enrichment at the CpTpT site [31,33,39]. This mutational signature is relatively rare in other
cancers, but some microsatellite-stable gastric cancers exhibit the same pattern [38]. These findings
suggest that some factors related to duodenogastro-esophageal reflux and its resultant inflammation
or unknown mutagens are associated with carcinogenesis in these regions. The fact that the essential
mutations in cancer-related genes, such as TP53, CDKN2A, SMAD4 and PIK3CA, are not affected
by these transversions at XpTpT sites, however, makes it difficult to understand key factors in the
development of these cancers [39]. On the other hand, the predominant mutational signature of
esophageal squamous cell carcinoma is C:G>T:A transitions at XpCpG and TpCpX sites, followed
by C:G>G:C transversions [31,40–42]. C:G>T:A transitions at TpCpX sequences represent the
involvement of APOBEC3B in the development of esophageal squamous cell carcinoma, consistent
with the fact that APOBEC3B expression is upregulated in these tumors [41]. The cause of C:G>G:C
transversions, however, remains unknown. Interestingly, C:G>A:T transversions, which are dominantly
detected in lung squamous cell carcinoma, are not predominant patterns in esophageal squamous cell
carcinoma [28,39]. These findings suggest that some mutagenic processes other than those associated
with tobacco carcinogens are involved in the development of esophageal squamous cell carcinoma,
although further investigation is needed.
The mutational patterns of hepatocellular carcinomas are quite different from those of gastrointestinal
cancers, although both cancer types are deeply associated with chronic inflammation. In addition
to C:G>T:A transitions in XpCpG contexts, T:A>C:G transitions in ApTpX contexts and T:A>A:T
transversions in CpTpG contexts are characteristic patterns in hepatocellular carcinoma [9,13,43,44].
Recent reports indicate that these mutational patterns are associated with ancestry and sex, but not
with viral status [44]. While C:G>T:A transitions in XpCpG contexts are commonly observed
across all ancestry and sexes, T:A>C:G transitions in ApTpA contexts and T:A>A:T transversions in
CpTpG contexts are especially increased in Japanese males and US-Asian cases, respectively [44].
These findings suggest that intra-ancestry diversity and/or environmental factors are associated with
the development of hepatocellular carcinoma. Interestingly, these mutational signatures are strongly
connected with transcriptional strand biases, suggesting the involvement of transcription-coupled DNA
repair that operates predominantly on the transcribed strand of the genes [13,44]. Considering that
transcription-coupled DNA repair generally works on bulky DNA helix-distorting lesions, unknown
extrinsic mutagens may be related to hepatocellular carcinogenesis.
Although the mutation pattern of each cancer provides useful information about carcinogenic
mechanisms, several kinds of mutational signatures often coexist in a particular cancer and
characteristics of genetic alterations varies according to molecular and histological subtypes. For
example, in gastric cancers, microsatellite-stable cancers exhibit chromosomal instability and T:A>G:C
transversions at the CpTpT site; microsatellite-instable cancers have features of chromosomal stability
and a large number of single nucleotide substitutions with relatively high T:A>C:G transition rates;
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diffuse-type cancers have relatively fewer single nucleotide variants and copy number aberrations [38].
Although subtyping of cancers by mutational signatures has not been established yet, it is expected
that a cancer will be classified into some genetic subtypes based on mutational signatures and other
characteristics of genetic aberrations in addition to traditional classification.
4. Conclusions
NGS technologies have uncovered not only genetic alterations of tumor tissues, but also those with
low allele frequencies in noncancerous tissues. Moreover, mutational signatures determined by NGS
also provide the footprints of carcinogenic processes. Interpreting mutational signatures of noncancerous
tissues in combination with those of cancerous tissues will provide information about the processes of
initiation and promotion of various cancers. There are various patterns of mutational signatures observed
in human cancers whose mutagenic processes are not yet explained. Resolution of these remaining
mysteries will be helpful for elucidating carcinogenic mechanisms.
NGS technologies have also exerted a great effect on identification of major driver genes in various
cancers, however, to reveal rare remaining driver mutations may be difficult due to limits of sample
sizes [69]. On the other hand, biomarkers overexpressed in cancers could derive from a small proportion
of tumor cells which possess a certain genetic alteration. Thus, the NGS technologies which provide
high sequencing coverage can be a powerful tool to identify such genetic aberrations and the resultant
overexpression of biomarker proteins.
Acknowledgments
This work was supported by Japan Society for the Promotion of Science (JSPS) KAKENHI
(26293172), Grants-in-aid for Scientific Research on Innovative Areas from the Ministry of Education,
Culture, Sports Science and Technology (MEXT) of Japan (22114006), and Grant-in-Aid for JSPS
Fellows (26.2212).
Conflicts of Interest
The authors declare no conflict of interest.
References
1. Parsons, D.W.; Jones, S.; Zhang, X.; Lin, J.C.; Leary, R.J.; Angenendt, P.; Mankoo, P.; Carter, H.;
Siu, I.; Gallia, G.L.; et al. An integrated genomic analysis of human glioblastoma multiforme.
Science 2008, 321, 1807–1812. [CrossRef]
2. Watson, I.R.; Takahashi, K.; Futreal, P.A.; Chin, L. Emerging patterns of somatic mutations in
cancer. Nat. Rev. Genet. 2013, 14, 703–718. [CrossRef]
3. Wang, K.; Kan, J.; Yuen, S.T.; Shi, S.T.; Chu, K.M.; Law, S.; Chan, T.L.; Kan, Z.; Chan, A.S.Y.;
Tsui, W.Y.; et al. Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes
of gastric cancer. Nat. Genet. 2011, 43, 1219–1223. [CrossRef]
Cancers 2015, 7 1047
4. Zang, Z.J.; Cutcutache, I.; Poon, S.L.; Zhang, S.L.; McPherson, J.R.; Tao, J.; Rajasegaran, V.;
Heng, H.L.; Deng, N.; Gan, A.; et al. Exome sequencing of gastric adenocarcinoma identifies
recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nat. Genet. 2012,
44, 570–574. [CrossRef]
5. Wang, K.; Yuen, S.T.; Xu, J.; Lee, S.P.; Yan, H.H.N.; Shi, S.T.; Siu, H.C.; Deng, S.; Chu, K.M.;
Law, S.; et al. Whole-genome sequencing and comprehensive molecular profiling identify new
driver mutations in gastric cancer. Nat. Genet. 2014, 46, 573–582. [CrossRef]
6. Nagarajan, N.; Bertrand, D.; Hillmer, A.M.; Zang, Z.J.; Yao, F.; Jacques, P.-É.; Teo, A.S.M.;
Cutcutache, I.; Zhang, Z.; Lee, W.H.; et al. Whole-genome reconstruction and mutational
signatures in gastric cancer. Genome Biol. 2012, 13, R115. [CrossRef]
7. Shimizu, T.; Marusawa, H.; Matsumoto, Y.; Inuzuka, T.; Ikeda, A.; Fujii, Y.; Minamiguchi, S.;
Miyamoto, S.; Kou, T.; Sakai, Y.; et al. Accumulation of somatic mutations in TP53 in gastric
epithelium with Helicobacter pylori infection. Gastroenterology 2014, 147, 407–417. [CrossRef]
8. Guichard, C.; Amaddeo, G.; Imbeaud, S.; Ladeiro, Y.; Pelletier, L.; Maad, I.B.; Calderaro, J.;
Bioulac-Sage, P.; Letexier, M.; Degos, F.; et al. Integrated analysis of somatic mutations and focal
copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat. Genet.
2012, 44, 694–698. [CrossRef]
9. Fujimoto, A.; Totoki, Y.; Abe, T.; Boroevich, K.A.; Hosoda, F.; Nguyen, H.H.; Aoki, M.;
Hosono, N.; Kubo, M.; Miya, F.; et al. Whole-genome sequencing of liver cancers identifies
etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat.
Genet. 2012, 44, 760–764. [CrossRef]
10. Nakagawa, H.; Shibata, T. Comprehensive genome sequencing of the liver cancer genome. Cancer
Lett. 2013, 340, 234–240. [CrossRef]
11. Barrett, M.T.; Sanchez, C.A.; Prevo, L.J.; Wong, D.J.; Galipeau, P.C.; Paulson, T.G.;
Rabinovitch, P.S.; Reid, B.J. Evolution of neoplastic cell lineages in Barrett oesophagus. Nat.
Genet. 1999, 22, 106–109.
12. Leedham, S.J.; Graham, T.A.; Oukrif, D.; McDonald, S.A.C.; Rodriguez-Justo, M.; Harrison, R.F.;
Shepherd, N.A.; Novelli, M.R.; Jankowski, J.A.Z.; Wright, N.A. Clonality, founder mutations, and
field cancerization in human ulcerative colitis-associated neoplasia. Gastroenterology 2009, 136,
542–550. [CrossRef]
13. Alexandrov, L.B.; Nik-Zainal, S.; Wedge, D.C.; Aparicio, S.A.J.R.; Behjati, S.; Biankin, A.V.;
Bignell, G.R.; Bolli, N.; Borg, A.; Børresen-Dale, A.-L.; et al. Signatures of mutational processes
in human cancer. Nature 2013, 500, 415–421. [CrossRef]
14. Lawrence, M.S.; Stojanov, P.; Polak, P.; Kryukov, G.V.; Cibulskis, K.; Sivachenko, A.; Carter, S.L.;
Stewart, C.; Mermel, C.H.; Roberts, S.A.; et al. Mutational heterogeneity in cancer and the search
for new cancer-associated genes. Nature 2013, 499, 214–218. [CrossRef]
15. Greenman, C.; Stephens, P.; Smith, R.; Dalgliesh, G.L.; Hunter, C.; Bignell, G.; Davies, H.;
Teague, J.; Butler, A.; Stevens, C.; et al. Patterns of somatic mutation in human cancer genomes.
Nature 2007, 446, 153–158. [CrossRef]
16. Hecht, S.S. Tobacco carcinogens, their biomarkers and tobacco-induced cancer. Nat. Rev. Cancer
2003, 3, 733–744. [CrossRef]
Cancers 2015, 7 1048
17. Brash, D.E.; Rudolph, J.A.; Simon, J.A.; Lin, A.; McKenna, G.J.; Baden, H.P.; Halperin, A.J.;
Pontén, J. A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell
carcinoma. Proc. Natl. Acad. Sci. USA 1991, 88, 10124–10128. [CrossRef]
18. Pfeifer, G.P.; You, Y.-H.; Besaratinia, A. Mutations induced by ultraviolet light. Mutat. Res. 2005,
571, 19–31. [CrossRef]
19. Foulkes, W.D. Inherited susceptibility to common cancers. N. Engl. J. Med. 2008, 359, 2143–2153.
[CrossRef]
20. Coussens, L.M.; Werb, Z. Inflammation and cancer. Nature 2002, 420, 860–867. [CrossRef]
21. Chiba, T.; Marusawa, H.; Ushijima, T. Inflammation-associated cancer development in digestive
organs: Mechanisms and roles for genetic and epigenetic modulation. Gastroenterology 2012, 143,
550–563. [CrossRef]
22. Colotta, F.; Allavena, P.; Sica, A.; Garlanda, C.; Mantovani, A. Cancer-related inflammation, the
seventh hallmark of cancer: Links to genetic instability. Carcinogenesis 2009, 30, 1073–1081.
[CrossRef]
23. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell 2011, 144, 646–674.
[CrossRef]
24. Brentnall, T.A.; Haggitt, R.C.; Rabinovitch, P.S.; Kimmey, M.B.; Bronner, M.P.; Levine, D.S.;
Kowdley, K.V.; Stevens, A.C.; Crispin, D.A.; Emond, M.; et al. Risk and natural history of colonic
neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis. Gastroenterology
1996, 110, 331–338. [CrossRef]
25. Hussain, S.P.; Amstad, P.; Raja, K.; Ambs, S.; Nagashima, M.; Bennett, W.P.; Shields, P.G.;
Ham, A.J.; Swenberg, J.A.; Marrogi, A.J.; et al. Increased p53 mutation load in noncancerous
colon tissue from ulcerative colitis: A cancer-prone chronic inflammatory disease. Cancer Res.
2000, 60, 3333–3337. [PubMed]
26. Kou, T.; Marusawa, H.; Kinoshita, K.; Endo, Y.; Okazaki, I.-M.; Ueda, Y.; Kodama, Y.; Haga, H.;
Ikai, I.; Chiba, T. Expression of activation-induced cytidine deaminase in human hepatocytes during
hepatocarcinogenesis. Int. J. Cancer 2007, 120, 469–476. [CrossRef]
27. Hamada, S.; Masamune, A.; Shimosegawa, T. Inflammation and pancreatic cancer: Disease
promoter and new therapeutic target. J. Gastroenterol. 2014, 49, 605–617. [CrossRef]
28. Kandoth, C.; McLellan, M.D.; Vandin, F.; Ye, K.; Niu, B.; Lu, C.; Xie, M.; Zhang, Q.;
McMichael, J.F.; Wyczalkowski, M.A.; et al. Mutational landscape and significance across 12
major cancer types. Nature 2013, 502, 333–339. [CrossRef]
29. Yoshida, K.; Sanada, M.; Ogawa, S. Deep sequencing in cancer research. Jpn. J. Clin. Oncol.
2013, 43, 110–115. [CrossRef]
30. Bass, A.J.; Thorsson, V.; Shmulevich, I.; Reynolds, S.M.; Miller, M.; Bernard, B.; Hinoue, T.;
Laird, P.W.; Curtis, C.; Shen, H.; et al. Comprehensive molecular characterization of gastric
adenocarcinoma. Nature 2014, 513, 202–209. [CrossRef]
31. Agrawal, N.; Jiao, Y.; Bettegowda, C.; Hutfless, S.M.; Wang, Y.; David, S.; Cheng, Y.;
Twaddell, W.S.; Latt, N.L.; Shin, E.J.; et al. Comparative genomic analysis of esophageal
adenocarcinoma and squamous cell carcinoma. Cancer Discov. 2012, 2, 899–905. [CrossRef]
Cancers 2015, 7 1049
32. Streppel, M.M.; Lata, S.; Delabastide, M.; Montgomery, E.A.; Wang, J.S.; Canto, M.I.;
Macgregor-Das, A.M.; Pai, S.; Morsink, F.H.M.; Offerhaus, G.J.; et al. Next-generation sequencing
of endoscopic biopsies identifies ARID1A as a tumor-suppressor gene in Barrett’s esophagus.
Oncogene 2014, 33, 347–357. [CrossRef]
33. Weaver, J.M.J.; Ross-Innes, C.S.; Shannon, N.; Lynch, A.G.; Forshew, T.; Barbera, M.;
Murtaza, M.; Ong, C.-A.J.; Lao-Sirieix, P.; Dunning, M.J.; et al. Ordering of mutations in
preinvasive disease stages of esophageal carcinogenesis. Nat. Genet. 2014, 46, 837–843.
[CrossRef]
34. Ikeda, A.; Shimizu, T.; Matsumoto, Y.; Fujii, Y.; Eso, Y.; Inuzuka, T.; Mizuguchi, A.; Shimizu, K.;
Hatano, E.; Uemoto, S.; et al. Leptin receptor somatic mutations are frequent in HCV-infected
cirrhotic liver and associated with hepatocellular carcinoma. Gastroenterology 2014, 146, 222–232.
[CrossRef]
35. Jiang, J.H.; Liu, Y.F.; Ke, A.W.; Gu, F.M.; Yu, Y.; Dai, Z.; Gao, Q.; Shi, G.M.; Liao, B.Y.;
Xie, Y.H.; et al. Clinical significance of the ubiquitin ligase UBE3C in hepatocellular carcinoma
revealed by exome sequencing. Hepatology 2014, 59, 2216–2227. [CrossRef]
36. Burns, M.B.; Temiz, N.A.; Harris, R.S. Evidence for APOBEC3B mutagenesis in multiple human
cancers. Nat. Genet. 2013, 45, 977–983. [CrossRef]
37. Poon, S.; McPherson, J.R.; Tan, P.; Teh, B.; Rozen, S.G. Mutation signatures of carcinogen
exposure: Genome-wide detection and new opportunities for cancer prevention. Genome Med.
2014, 6, 24. [CrossRef]
38. Wang, K.; Yuen, S.T.; Xu, J.; Lee, S.P.; Yan, H.H.N.; Shi, S.T.; Siu, H.C.; Deng, S.; Chu, K.M.;
Law, S.; et al. Whole-genome sequencing and comprehensive molecular profiling identify new
driver mutations in gastric cancer. Nat. Genet. 2014, 46, 573–582. [CrossRef]
39. Dulak, A.M.; Stojanov, P.; Peng, S.; Lawrence, M.S.; Fox, C.; Stewart, C.; Bandla, S.; Imamura, Y.;
Schumacher, S.E.; Shefler, E.; et al. Exome and whole-genome sequencing of esophageal
adenocarcinoma identifies recurrent driver events and mutational complexity. Nat. Genet. 2013,
45, 478–486. [CrossRef]
40. Gao, Y.; Chen, Z.; Li, J.; Hu, X.; Shi, X.; Sun, Z.; Zhang, F.; Zhao, Z.; Li, Z.; Liu, Z.; et al. Genetic
landscape of esophageal squamous cell carcinoma. Nat. Genet. 2014, 46, 1097–1102. [CrossRef]
41. Lin, D.-C.; Hao, J.-J.; Nagata, Y.; Xu, L.; Shang, L.; Meng, X.; Sato, Y.; Okuno, Y.; Varela, A.M.;
Ding, L.-W.; et al. Genomic and molecular characterization of esophageal squamous cell
carcinoma. Nat. Genet. 2014, 46, 467–473. [CrossRef]
42. Song, Y.; Li, L.; Ou, Y.; Gao, Z.; Li, E.; Li, X.; Zhang, W.; Wang, J.; Xu, L.; Zhou, Y.; et al.
Identification of genomic alterations in oesophageal squamous cell cancer. Nature 2014, 509,
91–95. [CrossRef]
43. Totoki, Y.; Tatsuno, K.; Yamamoto, S.; Arai, Y.; Hosoda, F.; Ishikawa, S.; Tsutsumi, S.; Sonoda, K.;
Totsuka, H.; Shirakihara, T.; et al. High-resolution characterization of a hepatocellular carcinoma
genome. Nat. Genet. 2011, 43, 464–469. [CrossRef]
44. Totoki, Y.; Tatsuno, K.; Covington, K.R.; Ueda, H.; Creighton, C.J.; Kato, M.; Tsuji, S.;
Donehower, L.A.; Slagle, B.L.; Nakamura, H.; et al. Trans-ancestry mutational landscape of
hepatocellular carcinoma genomes. Nat. Genet. 2014, 46, 1267–1273. [CrossRef]
Cancers 2015, 7 1050
45. Chan-On, W.; Nairismägi, M.-L.; Ong, C.K.; Lim, W.K.; Dima, S.; Pairojkul, C.; Lim, K.H.;
McPherson, J.R.; Cutcutache, I.; Heng, H.L.; et al. Exome sequencing identifies distinct mutational
patterns in liver fluke-related and non-infection-related bile duct cancers. Nat. Genet. 2013, 45,
1474–1478. [CrossRef]
46. Jiao, Y.; Pawlik, T.M.; Anders, R.A.; Selaru, F.M.; Streppel, M.M.; Lucas, D.J.; Niknafs, N.;
Guthrie, V.B.; Maitra, A.; Argani, P.; et al. Exome sequencing identifies frequent inactivating
mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nat. Genet. 2013,
45, 1470–1473. [CrossRef]
47. Olivier, M.; Weninger, A.; Ardin, M.; Huskova, H.; Castells, X.; Vallée, M.P.; McKay, J.;
Nedelko, T.; Muehlbauer, K.-R.; Marusawa, H.; et al. Modelling mutational landscapes of human
cancers in vitro. Sci. Rep. 2014, 4, 4482. [CrossRef]
48. Roberts, S.A.; Lawrence, M.S.; Klimczak, L.J.; Grimm, S.A.; Fargo, D.; Stojanov, P.; Kiezun, A.;
Kryukov, G.V.; Carter, S.L.; Saksena, G.; et al. An APOBEC cytidine deaminase mutagenesis
pattern is widespread in human cancers. Nat. Genet. 2013, 45, 970–976. [CrossRef]
49. Peltomäki, P. Role of DNA mismatch repair defects in the pathogenesis of human cancer. J. Clin.
Oncol. 2003, 21, 1174–1179. [CrossRef]
50. Imai, K.; Yamamoto, H. Carcinogenesis and microsatellite instability: The interrelationship
between genetics and epigenetics. Carcinogenesis 2008, 29, 673–680. [CrossRef]
51. Shah, S.N.; Hile, S.E.; Eckert, K.A. Defective mismatch repair, microsatellite mutation bias, and
variability in clinical cancer phenotypes. Cancer Res. 2010, 70, 431–435. [CrossRef]
52. Heitzer, E.; Tomlinson, I. Replicative DNA polymerase mutations in cancer. Curr. Opin. Genet.
Dev. 2014, 24, 107–113. [CrossRef]
53. Palles, C.; Cazier, J.-B.; Howarth, K.M.; Domingo, E.; Jones, A.M.; Broderick, P.; Kemp, Z.;
Spain, S.L.; Guarino, E.; Guarino Almeida, E.; et al. Germline mutations affecting the proofreading
domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. Nat. Genet.
2013, 45, 136–144. [CrossRef]
54. Nik-Zainal, S.; Alexandrov, L.B.; Wedge, D.C.; van Loo, P.; Greenman, C.D.; Raine, K.; Jones, D.;
Hinton, J.; Marshall, J.; Stebbings, L.A.; et al. Mutational processes molding the genomes of 21
breast cancers. Cell 2012, 149, 979–993. [CrossRef]
55. Krauthammer, M.; Kong, Y.; Ha, B.H.; Evans, P.; Bacchiocchi, A.; McCusker, J.P.; Cheng, E.;
Davis, M.J.; Goh, G.; Choi, M.; et al. Exome sequencing identifies recurrent somatic RAC1
mutations in melanoma. Nat. Genet. 2012, 44, 1006–1014. [CrossRef]
56. Jayaraman, S.S.; Rayhan, D.J.; Hazany, S.; Kolodney, M.S. Mutational landscape of basal cell
carcinomas by whole-exome sequencing. J. Invest. Dermatol. 2014, 134, 213–220. [CrossRef]
57. Pfeifer, G.P.; Denissenko, M.F.; Olivier, M.; Tretyakova, N.; Hecht, S.S.; Hainaut, P. Tobacco
smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene
2002, 21, 7435–7451. [CrossRef]
58. Shimizu, T.; Marusawa, H.; Endo, Y.; Chiba, T. Inflammation-mediated genomic instability: Roles
of activation-induced cytidine deaminase in carcinogenesis. Cancer Sci. 2012, 103, 1201–1206.
[CrossRef]
Cancers 2015, 7 1051
59. Takai, A.; Marusawa, H.; Chiba, T. Acquisition of Genetic Aberrations by Activation-Induced
Cytidine Deaminase (AID) during Inflammation-Associated Carcinogenesis. Cancers 2011, 3,
2750–2766. [CrossRef]
60. Muramatsu, M.; Kinoshita, K.; Fagarasan, S.; Yamada, S.; Shinkai, Y.; Honjo, T. Class switch
recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential
RNA editing enzyme. Cell 2000, 102, 553–563. [CrossRef]
61. Honjo, T.; Kinoshita, K.; Muramatsu, M. Molecular mechanism of class switch recombination:
Linkage with somatic hypermutation. Annu. Rev. Immunol. 2002, 20, 165–196. [CrossRef]
62. Matsumoto, Y.; Marusawa, H.; Kinoshita, K.; Endo, Y.; Kou, T.; Morisawa, T.; Azuma, T.;
Okazaki, I.-M.; Honjo, T.; Chiba, T. Helicobacter pylori infection triggers aberrant expression
of activation-induced cytidine deaminase in gastric epithelium. Nat. Med. 2007, 13, 470–476.
[CrossRef]
63. Endo, Y.; Marusawa, H.; Kinoshita, K.; Morisawa, T.; Sakurai, T.; Okazaki, I.-M.; Watashi, K.;
Shimotohno, K.; Honjo, T.; Chiba, T. Expression of activation-induced cytidine deaminase in
human hepatocytes via NF-kappaB signaling. Oncogene 2007, 26, 5587–5595. [CrossRef]
64. Liu, M.; Schatz, D.G. Balancing AID and DNA repair during somatic hypermutation. Trends
Immunol. 2009, 30, 173–181. [CrossRef]
65. Kim, S.K.; Nasu, A.; Komori, J.; Shimizu, T.; Matsumoto, Y.; Minaki, Y.; Kohno, K.; Shimizu, K.;
Uemoto, S.; Chiba, T.; et al. A model of liver carcinogenesis originating from hepatic progenitor
cells with accumulation of genetic alterations. Int. J. Cancer 2014, 134, 1067–1076. [CrossRef]
66. Shinohara, M.; Io, K.; Shindo, K.; Matsui, M.; Sakamoto, T.; Tada, K.; Kobayashi, M.;
Kadowaki, N.; Takaori-Kondo, A. APOBEC3B can impair genomic stability by inducing base
substitutions in genomic DNA in human cells. Sci. Rep. 2012, 2, 806. [CrossRef]
67. Morisawa, T.; Marusawa, H.; Ueda, Y.; Iwai, A.; Okazaki, I.; Honjo, T.; Chiba, T. Organ-specific
profiles of genetic changes in cancers caused by activation-induced cytidine deaminase expression.
Int. J. Cancer 2008, 123, 2735–2740. [CrossRef]
68. Shen, J.C.; Rideout, W.M.; Jones, P.A. The rate of hydrolytic deamination of 5-methylcytosine in
double-stranded DNA. Nucleic Acids Res. 1994, 22, 972–976. [CrossRef]
69. Wood, A.R.; Tuke, M.A.; Nalls, M.; Hernandez, D.; Gibbs, J.R.; Lin, H.; Xu, C.S.; Li, Q.; Shen, J.;
Jun, G.; et al. Whole-genome sequencing to understand the genetic architecture of common gene
expression and biomarker phenotypes. Hum. Mol. Genet. 2014, 24, 1504–1512. [CrossRef]
© 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article
distributed under the terms and conditions of the Creative Commons Attribution license
(http://creativecommons.org/licenses/by/4.0/).
